Abstract
We synthesized a new non-toxic biopolymer (GAP460) containing γ,L-glutamic acid and aspartate (Asp). Conjugates of GAP460 and cisplatin exhibited a drug-carrying capacity of nearly 40%, 3-times higher than γ-PGA and dramatically decreasing the amount of biopolymer required for high-dose delivery. Treatment with GAP460-cisplatin conjugate (PACC) not only effectively inhibited tumor growth in nude mice, but also resulted in extended survival and lower nephrotoxicity, suggesting that GAP460 could be used as an effective carrier for drug delivery and that PACC may have potential therapeutic applications in the clinical treatment of cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 2023-2040 |
| Number of pages | 18 |
| Journal | Journal of Biomaterials Science, Polymer Edition |
| Volume | 22 |
| Issue number | 15 |
| DOIs | |
| State | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Poly(γ,L-glutamic acid)
- aspartate conjugate
- cisplatin
- drug delivery
- toxicity
Fingerprint
Dive into the research topics of 'A novel GAP460 biopolymer for use as a carrier in drug-delivery applications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver